Treatment of Acute Myelogenous Leukemia

Research output: Contribution to journalLetterpeer-review

1 Citation (Scopus)

Abstract

To the Editor: The report by Zittoun et al. (Jan. 26 issue)1 on a comparison of allogeneic or autologous transplantation and chemotherapy for acute myelogenous leukemia (AML) illustrates a flaw in the study design that is common in trials of treatment for acute leukemia and that limits the clinical usefulness of the conclusions that are drawn. In the trial, all patients with histocompatible donors were assigned to the allogeneic-transplantation group and none were randomly assigned to the other two groups. This design is appropriate for studying the end point of duration of the first remission or of disease-free survival, but.

Original languageEnglish
Pages (from-to)1717
Number of pages1
JournalNew England Journal of Medicine
Volume332
Issue number25
DOIs
Publication statusPublished - 22 Jun 1995
Externally publishedYes

Fingerprint Dive into the research topics of 'Treatment of Acute Myelogenous Leukemia'. Together they form a unique fingerprint.

Cite this